Related Experiment Videos
Methylsulphasalazine in rheumatoid arthritis
1Clinical Pharmacology Unit (Rheumatism Research), Royal Bath Hospital, Harrogate, North Yorkshire, UK.
British Journal of Rheumatology
|December 1, 1990
Summary
Methylsulphasalazine shows promise for rheumatoid arthritis (RA) treatment, offering potential benefits with fewer side effects. Clinical improvements were noted, suggesting its efficacy as a second-line therapy.
Area of Science:
- Rheumatology
- Pharmacology
Background:
- Rheumatoid arthritis (RA) management seeks effective treatments with improved safety profiles.
- Sulphasalazine is a known RA therapeutic, but side effects can limit its use.
Purpose of the Study:
- To evaluate the efficacy and safety of methylsulphasalazine in patients with rheumatoid arthritis.
- To assess methylsulphasalazine as a potential second-line agent for RA.
Main Methods:
- A study involving 21 patients with rheumatoid arthritis receiving methylsulphasalazine therapy.
- Clinical assessments and biochemical markers (plasma viscosity, CRP, histidine, IgM) were monitored over 6 months.
Main Results:
- Ten patients completed 6 months of therapy; no serious adverse effects were reported.
- Statistically significant improvements in clinical assessments were observed from weeks 8-12.
- Significant reduction in plasma viscosity and trends toward improvement in serum CRP, histidine, and IgM concentrations were noted.
Conclusions:
- Methylsulphasalazine demonstrated clinical efficacy and a favorable safety profile in RA patients.
- The drug's performance suggests potential as a second-line agent for rheumatoid arthritis treatment.